Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Organogenesis Holdings Inc.NASDAQ: ORGO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $12.37M rose 96.9% year over year, ahead of the +45.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 76.4% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.
Context
- Depreciation & amortization amounted to 4.8% of revenue in FY2025, up 1.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +96.9% holds above the trailing-twelve-month pace of +45.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 26.94M USD
- Year-over-year change
- +58.2%
- 4-year CAGR
- +12.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.94M | +58.2% |
| FY2024 | 2024-12-31 | 17.03M | -27.4% |
| FY2023 | 2023-12-31 | 23.45M | +118.6% |
| FY2022 | 2022-12-31 | 10.73M | -35.7% |
| FY2021 | 2021-12-31 | 16.68M | — |
Depreciation & Amortization vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.2% is the 3rd highest of 10, against a peer median of -0.7%.
- Depreciation & amortization amounts to 6.0% of revenue for ORGO, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $93.9M USD | -11.7% | -12.6% | 13.9% | |
| LTM Mar 2026 | CA$56.2M CAD | -0.2% | +5.9% | 6.0% | |
| LTM Mar 2026 | $30.95M USD | +45.2% | +35.9% | 6.0% | |
| LTM Apr 2026 | $27.1M USD | -0.7% | -6.8% | 3.2% | |
| LTM Feb 2026 | $23.19M USD | -13.4% | -4.2% | 7.4% | |
| LTM Mar 2026 | $9.61M USD | +52.7% | +24.8% | 3.2% | |
| LTM Mar 2026 | $1.5M USD | +328.5% | -40.6% | 0.4% | |
| LTM Mar 2026 | $577.25K USD | +7.8% | +2.8% | 0.6% | |
| LTM Mar 2026 | $511.27K USD | -107.2% | +20.3% | 0.8% | |
| LTM Mar 2026 | $468K USD | -128.3% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ORGO) | — | -0.7% | -0.7% | 3.2% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.